the active pharmaceutical ingredients (API) and the medical device components.

Classification of Devices: Medical devices are classified based on risk (Classes I, IIa, IIb, III). The classification impacts the regulatory requirements, including the involvement of a Notified Body. Familiarize yourself with Article 117, which addresses the classification and requirements for drug-device combinations.

Essential Requirements and General Safety and Performance Requirements (GSPR): Article 5 emphasizes compliance with the GSPR as integral to demonstrating device safety and efficacy.

Post-Market Surveillance and Vigilance: Understand the ongoing responsibilities for monitoring the safety and effectiveness of drug-device combinations after they have been placed on the market.

Compliance with EUDAMED: This database is crucial for the registration of devices, vigilance reports, and information on the manufacturers and Notified Bodies. Compliance with EUDAMED is necessary for a transparent regulatory environment.

To ensure compliance, regulatory affairs professionals must develop proficient knowledge of how the MDR interplays with existing EU directives and national regulations.

Step 2: Engagement with Notified Bodies

The second step is the engagement process with Notified Bodies. Notified Bodies play a critical role in the conformity assessment for medical devices, particularly for those classified as higher risk. It is essential to identify a Notified Body that is appropriate for your product type and is designated under the EU MDR.

Actions to take include:

• Choosing the Right Notified Body: Consider the specific expertise of Notified Bodies, particularly in drug-device combinations. You can access a list of designated Notified Bodies on the European Commission’s website.
• Initial Meetings: Schedule preliminary discussions with the selected Notified Body to determine their expectations regarding documentation and quality management systems (QMS).
• Preparation of Technical Documentation: Prepare necessary documents for submission including the Summary of Safety and Clinical Performance (SSCP), a robust risk management file, and full clinical evaluation reports. Refer to EU MDR Annex II for detailed specifications on technical documentation.

The interaction with Notified Bodies is not just a requirement; it serves as an opportunity to align strategic goals and expectations. Developing a strong relationship early can facilitate smoother reviews during the assessment phase.

Step 3: Document Preparation and Compilation

The preparation and compilation of essential documentation is crucial in ensuring compliance with the EU MDR. Such documents serve to demonstrate adherence to the GSPR and successful risk management. The documentation requirements can be daunting but are essential for regulatory approval.

Key documents needed include:

• Technical File: Document your technical file according to Article 10 and Annex II of the EU MDR. Include details such as product description, intended use, design specifications, manufacturing processes and verification, as well as labeling and packaging information.
• Risk Management File: Develop a comprehensive risk management process aligned with ISO 14971. This should cover the identification, assessment, control, and monitoring of risks associated with the device.
• Clinical Evaluation Report (CER): Construct a robust CER in accordance with MEDDEV guidelines, ensuring it includes relevant scientific literature and clinical data supporting the safety and performance of the drug-device combination.
• Post-Market Surveillance Plan: Ensure that a well-thought-out post-market surveillance plan is in place to continuously monitor the safety and performance of the device once it reaches the market. Refer to the guidance provided in the EU MDR.

Documentation should be meticulously organized and regularly updated to reflect the most current product information and clinical data.

Step 4: Submission of the Technical Documentation

The next step involves the formal submission of technical documentation to the chosen Notified Body. The submission is a critical milestone in the regulatory process and demands a keen attention to detail.

Follow these guidelines for submission:

• Submission Method: Confirm the submission method preferred by the Notified Body—batch submission or staggered submissions—and prepare documents accordingly.
• Ensure Completeness: Cross-check the technical documentation against the Notified Body’s document checklist to ensure completeness. Incomplete submissions can lead to delays or refusals.
• Meaningful Communication: Maintain open lines of communication with the Notified Body post-submission. Address any requests for additional information promptly to avoid prolonging the review process.

Adhering to submission timelines and maintaining comprehensive communication will facilitate a more efficient review process.

Step 5: Regulatory Review and Approval Process

Once the submission is completed, the next phase is the regulatory review and approval process. During this stage, the Notified Body will conduct a thorough evaluation of the technical documentation, including the clinical data provided.

Key considerations during this phase include:

• Evaluation Timeline: Understand the timelines set by the Notified Body for review and keep track of the evaluation progress. Regular follow-ups can be beneficial.
• Addressing Queries: Prepare to respond quickly and efficiently to any queries or requests for additional information from the Notified Body. Ensuring that responses are scientifically substantiated is crucial.
• Compliance Checks: Expect detailed assessments regarding compliance with the GSPR and demonstrating clinical safety and performance. Be ready to substantiate claims made in the documentation.

The focus during this stage should be on ensuring that the evidence is compelling and that it robustly supports the clinical claims of safety and efficacy.

Step 6: Post-Market Commitments and Surveillance

The final step in the regulatory pathway involves ongoing post-market commitments and surveillance to ensure long-term product safety and compliance with the EU MDR.

Actions to undertake include:

• Implementation of Post-Market Surveillance Plans: Rigorously implement the post-market surveillance plan as detailed in your documentation, focusing on the collection of real-world data regarding device safety and efficacy.
• Risk Management Updates: Revise risks and the mitigation strategies in your risk management file based on post-market data and any adverse events reported.
• Reporting Obligations: Comply with reporting obligations related to incidents and adverse events as outlined in the EU MDR. This includes vigilance reporting within a defined timeline.

Engaging with stakeholders for periodic reviews and updates can facilitate adherence to regulatory requirements and foster a culture of safety and quality management.

In conclusion, the regulatory landscape surrounding drug-device combinations under the EU MDR necessitates a thorough understanding of the regulatory framework, proactive engagement with Notified Bodies, careful documentation, and vigilant post-market surveillance. Regulatory affairs professionals leveraging EU MDR consulting services stand better placed to navigate the complexities of compliance and ensure successful market access.